At the end of June we gathered with the homocystinuria community during the HCU Network America patient and expert conference in Colorado. We were moved to hear from Albert Freedman, Alex Orange Drink, leaders in #newbornscreening, diagnostics, and our very own Sagar Vaidya, VP of clinical development, who gave a talk about our Phase 3 clinical program examining an investigational enzyme replacement therapy for classical HCU. #MovingMountains2024 #InRareForLife
Travere Therapeutics’ Post
More Relevant Posts
-
I might have said this before, but I’ll say it again… You don’t want to miss this webinar! Working directly with patients to determine their best treatment options including all acces mechanisms is the future. We all deserve the level of consideration and opportunity that will be detailed in this presentation. Make sure you don’t let this one slip through the cracks. #patientcentric #telehealth #geneticcounseling #healthtech
Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this FREE webinar Sara Riordan, MS, CGC, Genome Medical; Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment, discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register now ⤵ https://lnkd.in/gRg3gwC4
-
-
Annovis Bio, Inc. announced that it has completed the final patient study visit in its Phase 3 trial of buntanetap (also known as ANVS401 and Posiphen) for early #ParkinsonsDisease. Buntanetap is unique in that it targets multiple neurotoxic proteins—amyloid β, tau, alpha-synuclein, and TDP43. The once-daily oral treatment is also being studied in Alzheimer’s disease and #DementiaWithLewyBodies. Study results are expected in January 2024. Read more at https://lnkd.in/g7WvTc5s #parkinsonsresearch #parkinsons #alphasynuclein #synucleinopathies https://lnkd.in/eKD2QwR
-
-
Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this FREE webinar Sara Riordan, MS, CGC, Genome Medical; Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment, discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register now ⤵ https://lnkd.in/gRg3gwC4
-
-
View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z
-
-
View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z
-
-
View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z
-
-
Join Dr. Young Wang, MD, and Dr. Ingela Mauritzon, PhD, on Wednesday, February 14 at 12:00 PM ET, as they guide you through the intricacies of in vitro diagnostics (IVD). This live webinar addresses the pressing need for standardized regulatory practices in the field of IVDs as advancements are made in an increasingly interconnected global healthcare landscape and demand grows for more precise diagnostics. Enroll today (with or without contact hours) > https://bit.ly/3RV3Sm5 #ACRP #Webinar #ContinuingEducation #InVitroDiagnostics #IVD
-
-
Have you watched any of our trial-overview videos, such as the STELLAR-305 study, designed to engage patients and empower them to start conversations with their care providers? Learn more here: https://buff.ly/4bKB08r #carcinoma #research #clinicaltrials #pharma #biotech #oncology CancerCare
myTRIAList Clinical Trial: STELLAR-305
https://www.youtube.com/
-
In ERA 2024's best-ranked abstract, we presented 72-week eGFR stabilization from our Phase 2b clinical trial for #IgANephropathy. We also showed rapid hematuria improvement and significantly higher hematuria resolution compared to placebo during the 36-week randomized period. Read the press release here: https://lnkd.in/eRcDMqd5 #ERA24
-
Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this webinar Sara Riordan MS, CGC, Genome Medical; Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register: https://lnkd.in/gRg3gwC4
-
